Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer Inc. (NYSE: PFE) has advanced to multiple ascending doses in a Phase 1 study of PF-07321332, a novel oral antiviral targeting SARS-CoV-2, after successfully completing single ascending dose testing. The study, conducted in the U.S., assesses safety, tolerability, and pharmacokinetics. This potential first-in-class therapy aims to provide oral treatment for COVID-19, complementing existing vaccines. Preclinical data supports its antiviral efficacy, with further findings to be presented at the Spring American Chemical Society meeting on April 6.
Pfizer invites investors and the public to its conference call on May 4, 2021, at 10 a.m. EDT. This call aims to discuss the First Quarter 2021 Performance Report. Interested participants can join via phone at (833) 711-4984 or (916) 900-3769, using the password 'First Quarter Earnings'. The report and webcast details are available at www.pfizer.com/investors. Pfizer is dedicated to improving global health through innovative medicines and vaccines, demonstrating its commitment for over 170 years.
The Israel Ministry of Health, Pfizer, and BioNTech announced significant findings from a real-world study showing a 97% effectiveness of the Pfizer-BioNTech COVID-19 Vaccine in preventing symptomatic COVID-19, severe cases, and deaths. This data, derived from health surveillance from January to March 2021, showcases the impact of Israel's vaccination efforts, particularly against the B.1.1.7 variant. Further, the vaccine demonstrated 94% effectiveness against asymptomatic infections, emphasizing its role in controlling the pandemic and supporting ongoing immunization campaigns globally.
Pfizer (NYSE: PFE) will host a webcast featuring CFO Frank D’Amelio at the Barclays Global Healthcare Conference on March 11, 2021, at 1:15 p.m. EST. Investors and the public can access the discussion via www.pfizer.com/investors. The archived recording will also be available on the same site after the event. Pfizer aims to enhance health care through innovative medicines and vaccines, maintaining a commitment to quality and safety in the biopharmaceutical industry for over 170 years.
The FDA has approved Pfizer's LORBRENA (lorlatinib) for first-line treatment of ALK-positive non-small cell lung cancer (NSCLC), expanding its indication for adults with metastatic disease. LORBRENA's transition from accelerated to full approval is based on the pivotal Phase 3 CROWN trial, which demonstrated a 72% reduction in progression or death compared to XALKORI. The drug targets common tumor mutations and is effective against brain metastases, presenting high response rates. Serious adverse events occurred in 34% of patients, with a 3.4% fatality rate.
Strata Oncology, Inc., a precision oncology firm, has launched the Strata PATH trial, a multi-drug and biomarker-driven clinical trial aimed at evaluating the effectiveness of FDA-approved therapies for specific cancer biomarkers. Pfizer (NYSE: PFE) will supply targeted drugs at no cost to participants. The trial is designed for patients with advanced solid tumors who have exhausted standard treatments. It utilizes Strata's comprehensive genomic profiling to match patients with investigational therapies, aiming to accelerate cancer treatment availability.
Pfizer announced the European Medicines Agency's acceptance of its Marketing Authorization Application for the 20-valent pneumococcal conjugate vaccine (20vPnC) targeting invasive disease and pneumonia in adults 18 and older. The review process by the Committee for Medicinal Products for Human Use begins, based on clinical data from over 6,000 participants in multiple trials. The 20vPnC vaccine addresses significant pneumococcal disease serotypes not included in existing vaccines, demonstrating Pfizer's ongoing commitment to vaccine innovation.
Pfizer (NYSE: PFE) and OPKO Health (NASDAQ: OPK) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application for somatrogon, a long-acting growth hormone for treating pediatric patients with growth hormone deficiency (GHD). If approved, somatrogon will allow once-weekly administration, reducing daily injection burdens. Results from a global Phase 3 trial showed somatrogon met its primary endpoint of height velocity non-inferiority compared to daily somatropin. A European Commission decision is anticipated in 2022.
Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) are evaluating a third dose of their COVID-19 vaccine, BNT162b2, to assess safety and immunity against circulating and emerging SARS-CoV-2 variants. This study will involve participants from a previous Phase 1 trial, who will receive the booster 6 to 12 months post-initial vaccination. Additionally, the companies are in talks with the FDA and EMA for a clinical study on a variant-specific vaccine. The goal is to ensure preparedness against future variants while maintaining current vaccine effectiveness.
Seven Bridges is partnering with Pfizer (NYSE: PFE) to enhance the management of single-cell RNA sequencing (scRNASeq) data. This collaboration aims to optimize Pfizer's cloud capabilities and data analysis through the cloud-based Seven Bridges Platform, which will handle terabytes of scRNASeq data and improve the understanding of gene expression. The initiative is expected to streamline data accessibility and reduce costs associated with sequencing data, bolstering Pfizer's research and development efforts in drug discovery.